ClinicalTrials.Veeva

Menu
P

ProScience Research Group | Culver City, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KarXT
SEP-363856
Cariprazine
Rapastinel
Lurasidone
Aticaprant
Brexpiprazole
BHV-7000
Ralmitaront
Roluperidone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 58 total trials

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipo...

Enrolling
Bipolar Disorder Type I With Mania
Drug: Valproate
Drug: Lamotrigine

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an a...

Enrolling
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Drug: KarXT
Other: Placebo

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Enrolling
Schizophrenia
Drug: SEP-363856
Other: Placebo

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \&...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: SEP-363856

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Enrolling
Schizophrenia
Drug: Cariprazine
Drug: Placebo

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)
Locations recently updated

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant (PF-07899801)

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive...

Enrolling
Major Depressive Disorder (MDD)
Drug: Ropanicant
Drug: Placebo

Trial sponsors

Otsuka logo
AbbVie logo
Karuna Therapeutics logo
Allergan logo
Boehringer Ingelheim logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Sumitomo Pharma logo
Biohaven logo
Biohaven logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems